Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6959-6969

  Ndhlovu, Zaza M ^a   Proudfoot, Jacqueline ^a   Cesa, Kevin ^a   Alvino, Donna Marie ^a   McMullen, Ashley ^a   Vine, Seanna ^a   Stampouloglou, Eleni ^a   Piechocka Trocha, Alicja ^a   Walker, Bruce D ^a,b   Pereyra, Florencia ^a,c  

^a HARVARD UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; TETRAMER;

ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL EXPANSION; CELL SELECTION; CELL SPECIFICITY; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; PEPTIDE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED;

EID: 84864020166     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00531-12     Document Type: Article

References (49)

1. Barouch DH, et al. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335- 339.
2. Betts MR, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781- 4789.
3. Blankson JN. 2011. The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine? Curr. Opin. HIV AIDS 6:147- 150.
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103- 6110.
5. Brass AL, et al. 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926.
6. Buzon MJ, et al. 2011. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J. Virol. 85:9646 -9650.
7. Calarota SA, et al. 2008. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J. Immunol. 180:5907-5915.
8. Cao W, et al. 2009. Premature aging of T cells is associated with faster HIV-1 disease progression. J. Acquir. Immune Defic. Syndr. 50:137-147.
9. Carrington M, O'Brien SJ. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535-551.
10. Chen H, et al. 2011. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J. Clin. Invest. 121:1549 -1560.
11. Chen H, et al. 2009. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J. Virol. 83:3138 -3149.
12. Day CL, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350 -354.
13. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416.
14. Elahi S, et al. 2011. Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat. Med. 17:989 -995.
15. Emu B, et al. 2005. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 79:14169 -14178.
16. Emu B, et al. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82:5398 -5407.
17. Freel SA, et al. 2010. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84:4998 -5006.
18. Goulder PJ, et al. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
19. Hansen SG, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527.
20. Hansen SG, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-299.
21. Jager S, et al. 2011. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375.
22. Jamieson BD, et al. 2003. Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. J. Immunol. 171: 5372-5379.
23. Julg B, et al. 2010. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J. Virol. 84:5540 -5549.
24. Kaech SM, et al. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4:1191-1198.
25. Kaufmann DE, et al. 2007. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8:1246 -1254.
26. Keating SM, et al. 2005. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175:5675-5680.
27. Koenig S, et al. 1995. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1:330 -336.
28. Koup RA, et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
29. Lambotte O, et al. 2005. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41:1053-1056.
30. Lecuroux C, et al. 2009. Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. Blood 113:3209 -3217.
31. Le Gall S, Stamegna P, Walker BD. 2007. Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest. 117:3563-3575.
32. Lopez M, et al. 2011. The expansion ability but not the quality of HIVspecific CD8(+) T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors. Immunology 134: 305-313.
33. Martin MP, et al. 1998. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-1911.
34. Migueles SA, et al. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061-1068.
35. Migueles SA, et al. 2008. Lytic granule loading of CD8+T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009 -1021.
36. Migueles SA, et al. 2000. HLA B* 5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97:2709 -2714.
37. Ndhlovu ZM, et al. 2011. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J. Immunol. 186: 6914-6924.
38. Pereyra F, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571.
39. Pereyra F, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557.
40. Saez-Cirion A, et al. 2011. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 118:955-964.
41. Saez-Cirion A, et al. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 104:6776- 6781.
42. Saez-Cirion A, et al. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182:7828 -7837.
43. Schmitz JE, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857- 860.
44. Streeck H, et al. 2008. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med. 5:e100. doi:10.1371/journal.pmed.0050100.
45. Streeck H, Frahm N, Walker BD. 2009. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat. Protoc. 4:461- 469.
46. Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G. 2005. Vaccine-induced CD8+central memory T cells in protection from simian AIDS. J. Immunol. 175:3502-3507.
47. Vigneault F, et al. 2011. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J. Virol. 85: 3015-3019.
48. Virgin HW, Walker BD. 2010. Immunology and the elusive AIDS vaccine. Nature 464:224 -231.
49. Vollbrecht T, et al. 2010. Impact of changes in antigen level on CD38/ PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection. J. Med. Virol. 82:358 -370.